Peanut Allergy Shot Meets Main Goal in Children
Aravax's PVX108 raised children's peanut tolerance more than placebo in a Phase 2 trial, with no treatment-related allergic reactions reported.
Updated on Nov. 16, 2026 in Allergies

Live Poll
Would you trust a monthly shot to help your child tolerate peanuts?
Melbourne biotech company Aravax Pty Ltd. reported that its investigational treatment PVX108 met the main goal of a Phase 2 peanut allergy trial in children. The trial enrolled 71 children aged 4 to 11 across 14 sites in the United States and Australia, and the FDA granted PVX108 fast track status in August 2026.
Why it matters
Peanut allergy affects roughly 2% of people in Western countries, and current management relies largely on strict avoidance. Results showing higher peanut tolerance in treated children, without reported treatment-related anaphylaxis, add to the evidence for immunotherapy approaches that could reduce that risk.
In the trial, 67% of reactions at the original trigger dose in the higher-dose group were graded zero or mild, compared with 35% in the placebo group. The 12-month extension results, expected in the second half of 2027, will show whether these gains persist.
The players
Aravax Pty Ltd.
Aravax is a biotechnology company spun out of Monash University in 2015 that is developing PVX108 as a peanut allergy treatment.
Andrew Forrest
Andrew Forrest is an Australian business figure and philanthropist, identified in the source as the home-country figure associated with the Australian trial site.
The details
PVX108 uses short synthetic fragments of peanut proteins designed to retrain the immune system without triggering the antibodies behind severe reactions. The most common side effects were reactions at the injection site, and no treatment-related allergic reactions, including anaphylaxis, or serious side effects were reported. Aravax was spun out of Monash University in 2015 and raised A$20 million ($13.8 million) in late 2022.
Timeline
2015: Aravax was spun out of Monash University.
Late 2022: Aravax raised A$20 million in a funding round.
August 2026: The FDA granted PVX108 fast track status.
12 November 2026: Aravax announced the Phase 2 trial met its main goal.
14 November 2026: Results were presented at the ACAAI meeting in Phoenix.
Roadmap
Existing peanut immunotherapy treatments such as Palforzia have shown desensitisation benefits but carry risks of allergic reactions during dosing. PVX108 instead uses short synthetic peptide fragments designed to retrain the immune system while avoiding the antibodies linked to severe reactions.
For families managing peanut allergy, the trial results do not change current avoidance advice, as PVX108 remains investigational. The treatment would require further trials and regulatory approval before it could be used outside research settings.
The takeaway
Families of children with peanut allergy should continue following current medical advice while watching for further trial data. Any future treatment will need longer-term safety and efficacy results before it reaches clinics.
What happens next
Results of a 12-month open-label extension of the PVX108 trial are expected in the second half of 2027.
Further reading
For more on how allergy research is progressing, explore our Allergies coverage.
Source note: This article includes information reported by Daily News on African Billionaires and UHNWIs.
Live Poll
Would you trust a monthly shot to help your child tolerate peanuts?










